Last reviewed · How we verify
MG-1
At a glance
| Generic name | MG-1 |
|---|---|
| Also known as | MG500mg,Placebo /bid P.O |
| Sponsor | PharmaKing |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers (PHASE1)
- Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome (PHASE2)
- A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS) (PHASE2, PHASE3)
- USG-Guided Shoulder Injections in Frozen Shoulder (NA)
- Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy (PHASE3)
- Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD (PHASE3)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MG-1 CI brief — competitive landscape report
- MG-1 updates RSS · CI watch RSS
- PharmaKing portfolio CI